Advances in the treatment of gastrointestinal stromal tumours.
Date
2007-09ICR Author
Author
Judson, I
Demetri, G
Type
Conference Proceeding
Metadata
Show full item recordAbstract
Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic gastrointestinal stromal tumour (GIST), improving survival time and delaying disease progression in many patients. Nevertheless, primary and secondary (acquired) resistance to imatinib is a substantial problem in routine clinical practice. Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that was approved for the treatment of imatinib-resistant or -intolerant GIST. In the pivotal phase III study, sunitinib provided substantial clinical benefits including disease control and superior survival versus placebo as second-line treatment. Treatment with sunitinib was reasonably well tolerated. The availability of sunitinib represents an important clinical advance in GIST management, providing physicians and patients with an effective therapy when resistance to imatinib develops.
Collections
Subject
Humans
Gastrointestinal Stromal Tumors
Disease Progression
Benzamides
Piperazines
Pyrimidines
Pyrroles
Indoles
Antineoplastic Agents
Disease-Free Survival
Imatinib Mesylate
Sunitinib
Research team
Sarcoma Clinical Trials
Language
eng
License start date
2007-09
Citation
Annals of oncology : official journal of the European Society for Medical Oncology, 2007, 18 Suppl 10 pp. x20 - x24